Volume 1, Issue 2, Pages 65-71 (November 2009)

2 of 6

ABSTRACT

ABSTRACT + REFS

FULL-TEXT PDF (209 KB)

The KRAS Mutation is Highly Correlated With EGFR Alterations in Patients With Non-small Cell Lung Cancer

Received 1 October 2009; received in revised form 26 October 2009; accepted 30 October 2009.

To understand epidermal growth factor receptor (EGFR) and KRAS alterations among tissues of lung cancer patients in Taiwan, and to further understand how they are related, we used tumor tissues from the non-small cell lung cancer patients and performed a complete analysis. In the experimental results, coexisting EGFR and KRAS mutations were found in 1% (2/180) of the samples. This shows that these mutations tend not to coexist. Furthermore, nearly no coexistence was found between KRAS mutations and EGFR overexpression. These outcomes greatly assist the efficacy prediction of current anti-EGFR drugs for cancer patients.

Key Words: EGFR , KRAS , non-small cell lung cancer

No full text is available. To read the body of this article, please view the PDF online.

Article Outline

• Abstract

• References

• Copyright

References

1. 1 Kim JE , Lee DH , Choi Y , et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis . Lung Cancer . 2009;65:351–354 . Abstract | Full Text | Full-Text PDF (196 KB) | CrossRef

2. 2 D'Andrea MR , Gasparini G . The future of anti-EGFR therapy . Int J Biol Markers . 2007;22(1 Suppl 4):S88–S93 . MEDLINE

3. 3 De Greve J , Decoster L , Van Meerbeek J , et al. Targeted therapies in the treatment of non-small cell lung cancer . Bull Cancer . 2008;95:358–364 [In French, English abstract] .

4. 4 Katzel JA , Fanucchi MP , Li Z . Recent advances of novel targeted therapy in non-small cell lung cancer . J Hematol Oncol . 2009;2:2 .

5. 5 Kanashiro CA , Schally AV , Zarandi M , et al. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer . Int J Oncol . 2007;30:1019–1028 . MEDLINE

6. 6 Meert AP , Feoli F , Martin B , et al. Angiogenesis in preinvasive, early invasive bronchial lesions and micropapillomatosis and correlation with EGFR expression . Histopathology . 2007;50:311–317 . MEDLINE | CrossRef

7. 7 Shibata T , Hanada S , Kokubu A , et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma . Cancer Sci . 2007;98:985–991 . MEDLINE | CrossRef

8. 8 Lee JW , Soung YH , Seo SH , et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas . Clin Cancer Res . 2006;12:57–61 . MEDLINE | CrossRef

9. 9 Soung YH , Lee JW , Nam SW , et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas . Oncology . 2006;70:285–289 .

10. 10 Soung YH , Lee JW , Kim SY , et al. Somatic mutations of the ERBB4 kinase domain in human cancers . Int J Cancer . 2006;118:1426–1429 . MEDLINE | CrossRef

11. 11 Wu CC , Hsu HY , Liu HP , et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications . Cancer . 2008;113:3199–3208 .

12. 12 Gallegos Ruiz MI , Floor K , Rijmen F , et al. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens . Cell Oncol . 2007;29:257–264 . MEDLINE

13. 13 Tang X , Varella-Garcia M , Xavier AC , et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas . Cancer Prev Res Phila Pa . 2008;1:192–200 .

14. 14 Uhara M , Matsuda K , Taira C , et al. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer . Clin Chim Acta . 2009;401:68–72 . CrossRef

15. 15 Zlobec I , Vuong T , Hayashi S , et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy . Br J Cancer . 2007;96:793–800 . MEDLINE | CrossRef

16. 16 Akslen LA , Puntervoll H , Bachmann IM , et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma . Melanoma Res . 2008;18:29–35 . CrossRef

17. 17 Patel DK . Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer . Pharmacotherapy . 2008;28(Suppl 11):S31–S41 .

18. 18 Linardou H , Dahabreh IJ , Kanaloupiti D , et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer . Lancet Oncol . 2008;9:962–972 . Abstract | Full Text | Full-Text PDF (213 KB) | CrossRef

19. 19 Spano JP , Milano G , Vignot S , et al. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer . Crit Rev Oncol Hematol . 2008;66:21–30 . Abstract | Full Text | Full-Text PDF (169 KB)

20. 20 Kosaka T , Yatabe Y , Onozato R , et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma . J Thorac Oncol . 2009;4:22–29 .

21. 21 Sambrook J , Fritsch EF , Maniatis T . In: Molecular Cloning: A Laboratory Manual . 6: New York: Cold Spring Harbor Laboratories Press; 1989;p. 22–34 .

22. 22 Soung YH , Lee JW , Kim SY , et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas . Virchows Arch . 2005;446:483–488 . MEDLINE | CrossRef

23. 23 Tang X , Varella-Garcia M , Xavier AC , et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas . Cancer Prev Res (Phila Pa) . 2008;1:192–200 .

24. 24 Buter J , Giaccone G . EGFR inhibitors in lung cancer . Oncology (Williston Park) . 2005;19:1707–1711 . MEDLINE

25. 25 Chen YF , Wang JY , Wu CH , et al. Detection of circulating cancer cells with K-ras oncogene using membrane array . Cancer Lett . 2005;229:115–122 . Abstract | Full Text | Full-Text PDF (267 KB) | CrossRef

26. 26 Wang JY , Hsieh JS , Chang MY , et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers . World J Surg . 2004;28:721–726 . MEDLINE

27. 27 Wang JY , Hsieh JS , Lu CY , et al. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients . Hepatogastroenterology . 2007;54:2259–2265 .

28. 28 Liu F , Jiang B , Gong SJ , et al. Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer . Zhonghua Yi Xue Yi Chuan Xue Za Zhi . 2007;24:31–34 [In Chinese, English abstract] . MEDLINE

29. 29 Wang JY , Wang YH , Jao SW , et al. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene . Oncol Rep . 2006;16:1245–1252 .

30. 30 Marchetti A , Martella C , Felicioni L , et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment . J Clin Oncol . 2005;23:857–865 . CrossRef

31. 31 Marchetti A , Felicioni L , Buttitta F . Assessing EGFR mutations . N Engl J Med . 2006;354:526–528 . CrossRef

32. 32 Han SW , Hwang PG , Chung DH , et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer . Int J Cancer . 2005;113:109–115 . MEDLINE | CrossRef

a Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

b Department of Orthopedic Surgery, Pingtung Christian Hospital, Pingtung, Taiwan

c School of Medical and Health Science, Fooyin University, Kaohsiung, Taiwan

d Department of Medical Research, Fooyin University Hospital, Pingtung, Taiwan

e School of Environmental and Life Sciences, Fooyin University, Kaohsiung, Taiwan

f Technology Development Center of Molecular Diagnosis and Fermentation Engineering, Fooyin University, Kaohsiung, Taiwan

g Department of Chest Medicine, Fooyin University Hospital, Pingtung, Taiwan

h Gene Target Technology Co. Ltd., Kaohsiung, Taiwan

i Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Corresponding authors. Jaw-Yuan Wang: Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tzyou 1st Road, Kaohsiung 807, Taiwan. Shiu-Ru Lin: School of Medical and Health Sciences, Fooyin University, 151 Chin-Hsueh Road, Ta-Liao Hsiang, Kaohsiung 831, Taiwan

† Ming-Je Yang and Chi-Kuei Hsu contributed equally to this work.

PII: S1877-8607(10)60002-1

doi:10.1016/S1877-8607(10)60002-1

2 of 6